Bharat Biotech to begin Covaxin trials in 2-18 age group in 10-12 days: Govt
Advertisement
New Delhi: Bharat Biotech is set to begin the phase II and III clinical trials for Covid-19 vaccine Covaxin in children in the age group of 2 to 18 years in the next 10-12 days, informed VK Paul, Member (Health), Niti Aayog on Tuesday.
"Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days," Paul said during a press conference.
Covaxin received the DCGI nod to conduct clinical trials in children on May 11. The Niti Ayog official further stated that the anti-Covid drug '2DG' developed by the Defence Research and Development Organisation (DRDO) has been granted permission for emergency use by the DCGI.
He also mentioned that the anti-Covid drug will be examined by the Covid-19 National Task Force for adding it to the treatment protocol.
"We will examine the drug in Covid-19 National Task Force for adding it to the treatment protocol. DCGI has granted permission for emergency use," said Paul.
Hours after Delhi Chief Minister, Arvind Kejriwal stated that the new Covid variant detected in Singapore is "deadly for children" and may bring in third wave of the disease in the country, Paul reassured that children will not get serious Covid-19 infection, adding that the situation is being closely monitored and reports referring to the variant are being examined.
"We are examining the report you are referring to about a particular variant. Regarding Covid-19 among children, it is being reassured that they do not get serious infection. We are keeping an eye on this," he said.
Amid concerns of a third wave of Covid-19 in the country, which according to many health experts is likely to target children, the Delhi Chief Minister requested the Central government to immediately suspend air services with Singapore and to work out vaccination options for children on priority.
Read also: Hester Biosciences, OmniBRx, Gujarat Govt in talks with Bharat Biotech to ramp up Covaxin production
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.